News | January 12, 2015

CardioFocus Partners with Japan Lifeline for Distribution of HeartLight Laser Balloon

Japan Lifeline to be exclusive distributor for atrial fibrillation device in country of more than 1 million estimated AF sufferers

CardioFocus, HeartLight Endoscopic Ablation System, Japan Lifeline, distribution

Image courtesy of CardioFocus Inc.

January 12, 2015 — CardioFocus Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation (AF), announced that it has executed an exclusive, multi-year distribution agreement with Japan Lifeline Co. Ltd. 

AF is the most common sustained arrhythmia and presents elevated risk factors for both stroke and death. It is estimated that more than 1 million people in Japan currently suffer from this debilitating disease. Individuals affected by AF have been increasing worldwide due to an aging population and continued increases in the prevalence and incidence of AF are expected.

Hiroshi Nakagawa, M.D., Ph.D., professor of medicine at the University of Oklahoma Health Sciences Center, director, Clinical Catheter Ablation Program, and director, translational electrophysiology commented:  "While conventional RF ablation technology to treat AF is widely used, it is typical for patients treated with conventional technology to have their arrhythmia recur after one and even after several ablations. The CardioFocus HeartLight is a unique ablation technology that promises to reduce the need for multiple procedures. Its direct endoscopic visualization enables precise placement of ablation energy. This results in the creation of continuous lesions around the pulmonary veins, which are essential for long-lasting elimination of AF. The compliant balloon guarantees an anatomical fit to all types of patient anatomies so the risk of delivering energy too far into the vein and causing complications is minimized. Laser energy creates lesions deep enough to treat the arrhythmia without excess damage to either the endocardial surface or structures surrounding the left atrium. Laser power may also be adjusted to match the differing requirements of various parts of the atrium. This capability increases the efficacy, (durable pulmonary vein isolation) and safety (reduction of collateral damage) for AF ablation procedures."

For more information: www.cardiofocus.com

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init